We have thus decided to study obesity in patients and to use the mouse model to evaluate if soluble FGFR3 therapy, an innovative treatment approach for achondroplasia, could also impact the development of this significant complication. The gene discussed is FGFR3; the disease is obesity due to melanocortin 4 receptor deficiency.